9月14日，中国生物制药盘中上涨3.14%，报5.415港元/股，成交额6393.24万港元。
消息面上，公司此前公告称，旗下全资子公司拟以44.8亿元人民币现金收购雍华创投有限公司100%股权，从而间接取得正大天晴5%股权，交易完成后公司间接持有正大天晴股权将由60%增至65%，预计于9月16日完成交割。以正大天晴过去十二个月经调整归母净利润计算，本次收购对应市盈率约19倍，可增厚集团经调整归母净利润约3.5亿元，占比约7.4%。此外，国盛证券首次覆盖给予"买入"评级，目标价8.20港元，看好公司创新管线进入密集兑现期。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.